abrdn plc Increases Position in Pfizer Inc. (NYSE:PFE)

abrdn plc grew its holdings in Pfizer Inc. (NYSE:PFE) by 108.1% in the fourth quarter, Holdings Channel.com reports. The institutional investor owned 4,469,299 shares of the biopharmaceutical company’s stock after acquiring an additional 2,321,671 shares during the quarter. abrdn plc’s holdings in Pfizer were worth $128,671,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also made changes to their positions in the company. Front Street Capital Management Inc. increased its stake in Pfizer by 4.3% in the 1st quarter. Front Street Capital Management Inc. now owns 5,168 shares of the biopharmaceutical company’s stock valued at $268,000 after buying an additional 215 shares during the period. Castleview Partners LLC increased its stake in Pfizer by 2.4% in the 1st quarter. Castleview Partners LLC now owns 12,207 shares of the biopharmaceutical company’s stock valued at $498,000 after buying an additional 287 shares during the period. United Bank increased its stake in Pfizer by 0.6% in the 1st quarter. United Bank now owns 46,671 shares of the biopharmaceutical company’s stock valued at $2,416,000 after buying an additional 290 shares during the period. Compton Capital Management Inc. RI increased its stake in Pfizer by 0.5% in the 1st quarter. Compton Capital Management Inc. RI now owns 63,891 shares of the biopharmaceutical company’s stock valued at $3,308,000 after buying an additional 300 shares during the period. Finally, GHP Investment Advisors Inc. increased its stake in Pfizer by 2.4% in the 4th quarter. GHP Investment Advisors Inc. now owns 13,332 shares of the biopharmaceutical company’s stock valued at $683,000 after buying an additional 307 shares during the period. 68.36% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

PFE has been the subject of several recent research reports. TD Cowen downgraded shares of Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 target price for the company. in a research report on Thursday, January 4th. Guggenheim initiated coverage on shares of Pfizer in a research report on Friday, February 23rd. They issued a “buy” rating and a $36.00 target price for the company. Argus downgraded shares of Pfizer from a “buy” rating to a “hold” rating in a research report on Friday, March 22nd. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and set a $45.00 price objective on shares of Pfizer in a report on Monday, April 15th. Twelve investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $36.88.

Pfizer Price Performance

Shares of PFE stock traded up $0.61 during mid-day trading on Friday, reaching $26.00. The company’s stock had a trading volume of 38,372,801 shares, compared to its average volume of 34,236,664. Pfizer Inc. has a 1-year low of $25.23 and a 1-year high of $40.37. The company has a market cap of $147.23 billion, a P/E ratio of 72.19, a PEG ratio of 1.14 and a beta of 0.61. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.69 and a current ratio of 0.91. The firm’s 50-day moving average is $27.11 and its two-hundred day moving average is $28.68.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, January 30th. The biopharmaceutical company reported $0.10 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.29. The company had revenue of $14.25 billion during the quarter, compared to analysts’ expectations of $14.37 billion. Pfizer had a net margin of 3.62% and a return on equity of 10.88%. The business’s revenue was down 41.3% on a year-over-year basis. During the same quarter in the prior year, the company posted $1.14 EPS. On average, research analysts predict that Pfizer Inc. will post 2.24 earnings per share for the current year.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.